News

1 to 9 of 33 results

Janssen partners with MacroGenics in up to $625 million deal

Janssen partners with MacroGenics in up to $625 million deal

23-12-2014

Shares of US biotech firm MacroGenics rocketed 11.7% to a 10-month high of $38.58 yesterday, on the news…

BiotechnologyGlobalJanssen BiotechJohnson & JohnsonLicensingMacroGenicsMergers & AcquisitionsMGD011Oncology

Johnson & Johnson to acquire Alios BioPharma

Johnson & Johnson to acquire Alios BioPharma

30-09-2014

US health care giant Johnson & Johnson has signed a definitive agreement to acquire Alios BioPharma,…

AL-8176Alios BioPharmaAnti-viralsJohnson & JohnsonMergers & AcquisitionsPharmaceuticalUSA

J&J affiliate Cilag GmbH International acquires Covagen

J&J affiliate Cilag GmbH International acquires Covagen

25-08-2014

Cilag GmbH International, an affiliate of US health care giant Johnson & Johnson’s Janssen companies,…

Anti-Arthritics/RheumaticsBiotechnologyCilag GmbH InternationalCovagenFynomAbInflammatory diseasesJanssenJohnson & JohnsonMergers & Acquisitions

Johnson & Johnson accepts $4 billion offer for Ortho-Clinical Diagnostics

Johnson & Johnson accepts $4 billion offer for Ortho-Clinical Diagnostics

01-04-2014

US health care giant Johnson & Johnson revealed yesterday that it has accepted the binding offer from…

Johnson & JohnsonMergers & AcquisitionsPharmaceutical

Johnson & Johnson offered $4.15 billion for its diagnostics unit

Johnson & Johnson offered $4.15 billion for its diagnostics unit

17-01-2014

After days of speculation about divestitures by US health care major Johnson & Johnson, the company last…

Johnson & JohnsonMergers & AcquisitionsPharmaceutical

Johnson & Johnson in deal to buy Aragon Pharma for up to $1 billion

18-06-2013

US health care giant Johnson & Johnson (NYSE: JNJ) has reached a definitive agreement to acquire Aragon…

Aragon PharmaceuticalsJohnson & JohnsonMergers & AcquisitionsOncologyPharmaceuticalSeragon Pharmaceuticals

Royalty bid for Elan could be withdrawn; J&J sells 25.4 million Elan shares

14-06-2013

Ireland-based hostile takeover target Elan (NYSE: ELN) fell 5.2% to 9.29 euros on June 13, the most in…

ElanJohnson & JohnsonMergers & AcquisitionsPharmaceuticalRoyalty Pharma

News briefs from Alimera on Iluvien and Xencor on Xtend; Galapagos milestone and acquisition

17-01-2013

US biopharma company Alimera Sciences (Nasdaq: ALIM) says that the Spanish Agency of Drugs and Medical…

Alimera SciencesBiotechnologyCangenixGalapagosIluvienJanssenJohnson & JohnsonMergers & AcquisitionsOphthalmicsPharmaceuticalRegulationResearchXencorXtend

1 to 9 of 33 results

COMPANY SPOTLIGHT

Menarini

Back to top